Literature DB >> 17465289

Indicated vs. routine prenatal urine chemical reagent strip testing.

Mary Ann Rhode1, Howard Shapiro, Oliver W Jones.   

Abstract

OBJECTIVE: To determine if urinary tract infection, high blood pressure and gestational diabetes mellitus (GDM) are underdiagnosed when prenatal urine testing is done on a clinically indicated vs. routine basis. STUDY
DESIGN: Prenatal and delivery records of 2,981 subjects were reviewed in a predominantly Hispanic and medically underserved population. Patients prior to August 2002 received routine urine screening. After August 2002, women were tested only if preestablished criteria were present.
RESULTS: The number of patients diagnosed with high blood pressure and urinary tract infection was equivalent in the 2 groups. Despite unchanged screening for GDM between groups, the incidence of GDM declined from 9.3% to 4.2%.
CONCLUSION: GDM, high blood pressure and urinary tract infection will not be underdiagnosed if prenatal urine testing is done on an indicated basis. It is safe to discontinue routine urine screening when a regimen of initial urine cultures, GDM screening at 24-28 weeks, indicated urine chemical reagent strip testing and routine blood pressure determination is used. Criteria for indicated urine testing should be clearly defined and consistently followed by all staff.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465289

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

1.  Recommendations on screening for asymptomatic bacteriuria in pregnancy.

Authors:  Ainsley Moore; Marion Doull; Roland Grad; Stéphane Groulx; Kevin Pottie; Marcello Tonelli; Susan Courage; Alejandra Jaramillo Garcia; Brett D Thombs
Journal:  CMAJ       Date:  2018-07-09       Impact factor: 8.262

2.  Asymptomatic bacteriuria in pregnancy: systematic reviews of screening and treatment effectiveness and patient preferences.

Authors:  Aireen Wingert; Jennifer Pillay; Meghan Sebastianski; Michelle Gates; Robin Featherstone; Kassi Shave; Ben Vandermeer; Lisa Hartling
Journal:  BMJ Open       Date:  2019-03-13       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.